Top

Published in:

01-08-2014 | Laboratory Investigation

The overexpression of Epithelial cell adhesion molecule (EpCAM) in glioma

Authors: Xin Chen, Wei-Yuan Ma, Shang-Chen Xu, Yu Liang, Yi-Bing Fu, Bo Pang, Tao Xin, Hai-Tao Fan, Rui Zhang, Jian-Gang Luo, Wen-Qing Kang, Min Wang, Qi Pang

Published in: Journal of Neuro-Oncology | Issue 1/2014

Abstract

Epithelial cell adhesion molecule (EpCAM) is overexpressed in various neoplasms as a tumor-associated antigen and absent in natural brain. However, little is known about EpCAM’s expression in gliomas. To investigate the expression of EpCAM in gliomas and understand the correlation of EpCAM expression with malignancy, proliferation, angiogenesis, and prognosis, we studied the expression of EpCAM in 98 glioma samples by immunohistochemistry and by western blotting (N = 12). Correlative analysis of EpCAM overexpression with microvessel density (MVD), Ki-67 expression, age, and gender were made. Survival data was analyzed with Kaplan–Meier method and Cox Proportional Hazard Model. Immunohistochemistry results showed EpCAM was widely expressed in glioma (90.8 %). The overexpression rate of WHO grade IV gliomas was significantly higher EpCAM overexpression correlated significantly with Ki-67 expression and MVD. Western blot analysis also revealed a stepwise increase in EpCAM expression from WHO II to IV glioma. The overall survival of WHO III and IV glioma patients with EpCAM overexpression was obviously lower than that without EpCAM overexpression. EpCAM overexpression was an independent prognostic factor for overall survival in glioma patients. This study firstly shows that EpCAM overexpression correlates significantly with malignancy (WHO grades), proliferation (Ki67), angiogenesis (MVD), and prognosis in gliomas. EpCAM may participate in tumorgenesis of gliomas.

Ohgaki H (2009) Epidemiology of brain tumors. Methods Mol Biol 472:323–342. doi:10.1007/978-1-60327-492-0_14 PubMedCrossRef

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) World Health Organization Classification of Tumours: Pathology and genetics of tumours of the nervous system. International Agency for Research on Cancer (IARC), Lyon

Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507. doi:10.1056/NEJMra0708126 PubMedCrossRef

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef

Rousseau A, Mokhtari K, Duyckaerts C (2008) The 2007 WHO classification of tumors of the central nervous system—what has changed? Curr Opin Neuro 21(6):720–727. doi:10.1097/WCO.0b013e328312c3a7 CrossRef

Labussiere M, Wang XW, Idbaih A, Ducray F, Sanson M (2010) Prognostic markers in gliomas. Future Oncol 6(5):733–739. doi:10.2217/fon.10.25 PubMedCrossRef

Phillips HS, Kharbanda S, Chen R et al (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9(3):157–173. doi:10.1016/j.ccr.2006.02.019 PubMedCrossRef

Carpenter G, Red Brewer M (2009) EpCAM: another surface-to-nucleus missile. Cancer Cell 15(3):165–166. doi:10.1016/j.ccr.2009.02.005 PubMedCrossRef

Gires O, Klein CA, Baeuerle PA (2009) On the abundance of EpCAM on cancer stem cells. Nat Rev Cancer 9:143. doi:10.1038/nrc2499-c1 PubMedCrossRef

10.

Schnell U, Kuipers J, Giepmans BN (2013) EpCAM proteolysis: new fragments with distinct functions? Biosci Rep 33(2):e00030. doi:10.1042/BSR20120128

11.

Herlyn D, Herlyn M, Steplewski Z, Koprowski H (1979) Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. Eur J Immunol 9:657–659. doi:10.1002/eji.1830090817 PubMedCrossRef

12.

Baeuerle PA, Gires O (2007) EpCAM (CD326) finding its role in cancer. Br J Cancer 96:417–423. doi:10.1038/sj.bjc.6603494 PubMedCentralPubMedCrossRef

13.

van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG (2010) EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 31(11):1913–1921. doi:10.1093/carcin/bgq187 PubMedCrossRef

14.

Patriarca C, Macchi RM, Marschner AK, Mellstedt H (2012) Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 38(1):68–75. doi:10.1016/j.ctrv.2011.04.002 PubMedCrossRef

15.

Osta WA, Chen Y, Mikhitarian K et al (2004) EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64:5818–5824. doi:10.1158/0008-5472.CAN-04-0754 PubMedCrossRef

16.

Münz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O (2004) The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23:5748–5758. doi:10.1038/sj.onc.1207610 PubMedCrossRef

17.

Gastl G, Spizzo G, Obrist P, Dünser M, Mikuz G (2000) EpCAM overexpression in breast cancer as a predictor of survival. Lancet 356:1981–1982. doi:10.1016/S0140-6736(00)03312-2 PubMedCrossRef

18.

Spizzo G, Fong D, Wurm M et al (2011) EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol 64(5):415–420. doi:10.1136/jcp.2011.090274 PubMedCentralPubMedCrossRef

19.

Yanamoto S, Kawasaki G, Yoshitomi I, Iwamoto T, Hirata K, Mizuno A (2007) Clinicopathologic significance of EpCAM expression in squamous cell carcinoma of the tongue and its possibility as a potential target for tongue cancer gene therapy. Oral Oncol 43:869–877. doi:10.1016/j.oraloncology.2006.10.010 PubMedCrossRef

20.

Yamashita T, Budhu A, Forgues M, Wang XW (2007) Activation of Hepatic Stem Cell Marker EpCAM by Wnt Signaling in Hepatocellular Carcinoma. Cancer Res 67(22):10831–10839. doi:10.1158/0008-5472 PubMedCrossRef

21.

Imrich S, Hachmeister M, Gires O (2012) EpCAM and its potential role in tumor-initiating cells. Cell Adh Migr 6(1):30–38. doi:10.4161/cam.18953 PubMedCentralPubMedCrossRef

22.

Maetzel D, Denzel S, Mack B et al (2009) Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 11(2):162–171. doi:10.1038/ncb1824 PubMed

23.

Went PT, Lugli A, Meier S et al (2004) Frequent EpCam protein expression in human carcinomas. Hum Pathol 35(1):122–128. doi:10.1016/j.humpath.2003.08.026 PubMedCrossRef

24.

Subirá D, Serrano C, Castañón S et al (2012) Role of flow cytometry immunophenotyping in the diagnosis of leptomeningeal carcinomatosis. Neuro Oncol 14(1):43–52. doi:10.1093/neuonc/nor172 PubMedCentralPubMedCrossRef

25.

Kurtz JE, Dufour P (2010) Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther 10(6):951–958. doi:10.1517/14712598.2010.482098 PubMedCrossRef

26.

Chaudhry IH, O’Donovan DG, Brenchley PE, Reid H, Roberts IS (2001) Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 39:409–415. doi:10.1046/j.1365-2559.2001.01230.x PubMedCrossRef

27.

Rahmah NN, Sakai K, Sano K, Hongo K (2012) Expression of RECK in endothelial cells of glioma: comparison with CD34 and VEGF expressions. J Neurooncol 107(3):559–564. doi:10.1007/s11060-011-0778-z PubMedCrossRef

28.

Netto GC, Bleil CB, Hilbig A, Coutinho LM (2008) Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas. Neuropathology 28:17–23. doi:10.1111/j.1440-1789.2007.00825.x PubMedCrossRef

29.

Vermeulen PB, Gasparini G, Fox SB et al (1996) Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A:2474–2484PubMedCrossRef

30.

Deb P, Boruah D, Dutta V (2012) Morphometric study of microvessels in primary CNS tumors and its correlation with tumor types and grade. Microvasc Res 84(1):34–43. doi:10.1016/j.mvr.2012.03.004 PubMedCrossRef

31.

Varga Z, Diebold J, Dommann-Scherrer C et al (2012) How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast-and Gynecopathologists. PLoS One 7:e37379. doi:10.1371/journal.pone.0037379 PubMedCentralPubMedCrossRef

32.

Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311–322. doi:10.1002/(SICI)1097-4652(200003)182:3<311:AID-JCP1>3.0.CO;2-9 PubMedCrossRef

33.

Hou XZ, Liu W, Fan HT et al (2010) Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas. Neuro Oncol 12(8):799–803. doi:10.1093/neuonc/noq024 PubMedCentralPubMedCrossRef

34.

Pang B, Fan H, Zhang IY et al (2012) HMGA1 expression in human gliomas and its correlation with tumor proliferation, invasion and angiogenesis. J Neurooncol 106(3):543–549. doi:10.1007/s11060-011-0710-6 PubMedCrossRef

35.

Fong D, Steurer M, Obrist P et al (2008) Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J Clin Pathol 61(1):31–35. doi:10.1136/jcp.2006.037333 PubMedCrossRef

36.

Varga Meri, Obrist Peter, Schneeberger Stephan et al (2004) Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 10:3131–3136. doi:10.1158/1078-0432 PubMedCrossRef

37.

Spizzo G, Went P, Dirnhofer S, Obrist P et al (2006) Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 103(2):483–488. doi:10.1016/j.ygyno.2006.03.035 PubMedCrossRef

38.

McGirt MJ, Chaichana KL, Gathinji M et al (2009) Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 110(1):156–162. doi:10.3171/2008.4.17536 PubMedCrossRef

Title: The overexpression of Epithelial cell adhesion molecule (EpCAM) in glioma
Authors: Xin Chen
Wei-Yuan Ma
Shang-Chen Xu
Yu Liang
Yi-Bing Fu
Bo Pang
Tao Xin
Hai-Tao Fan
Rui Zhang
Jian-Gang Luo
Wen-Qing Kang
Min Wang
Qi Pang
Publication date: 01-08-2014
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2014
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-014-1459-5

At a glance: The STEP trials

Springer Medicine

The overexpression of Epithelial cell adhesion molecule (EpCAM) in glioma

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

1p34.2 rs621559 and 14q21 rs398652 leukocyte telomere length-related genetic variants contribute to glioma susceptibility

Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab

Identifying the survival subtypes of glioblastoma by quantitative volumetric analysis of MRI

Spin-echo echo-planar perfusion prior to chemoradiation is a strong independent predictor of progression-free and overall survival in newly diagnosed glioblastoma

Elderly patients aged 65–75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide

Bevacizumab treatment leads to observable morphological and metabolic changes in brain radiation necrosis